Pub Date : 2023-02-05DOI: 10.37290/ijpp2641-7197.18:7-13
T. Koike, S. Yamamoto, T. Furui, C. Miyazaki, H. Ishikawa, K. Morishige
This study aimed to evaluate whether equol production status has an impact on the risk of locomotive syndrome in very elderly (≥85 years old) women. In this retrospective observational study, 116 very elderly women were recruited from those who lived in nursing homes for the elderly from June 2018 to November 2019. Equol production status was determined by measuring spot urine levels of equol, and risks of locomotive syndrome were evaluated by vulnerable fracture history and loco-check, a simple questionnaire comprising seven questions that can describe locomotive syndrome. Equol production (≥1 μmol/L in a spot urine sample) was found in 46 women (39.6%). Loss of equol production contributes to some lococheck items, which correlate with weakness of lower limb muscle strength (P < 0.05). In this study population, 57 women (49.1%) had previous vulnerable fractures. However, equol production status was not significantly related to the vulnerable fracture in this study population (P = 0.159). Equol production might contribute to the induction of locomotive syndrome, at least in part. However, equol deficiency as a mechanism of locomotive syndrome induction might not be the primary cause of a previous vulnerable fracture in very elderly women who live in nursing homes.
{"title":"Evaluation of the Relationship Between Equol Production and the Risk of Locomotive Syndrome in Very Elderly Women","authors":"T. Koike, S. Yamamoto, T. Furui, C. Miyazaki, H. Ishikawa, K. Morishige","doi":"10.37290/ijpp2641-7197.18:7-13","DOIUrl":"https://doi.org/10.37290/ijpp2641-7197.18:7-13","url":null,"abstract":"This study aimed to evaluate whether equol production status has an impact on the risk of locomotive syndrome in very elderly (≥85 years old) women. In this retrospective observational study, 116 very elderly women were recruited from those who lived in nursing homes for the elderly from June 2018 to November 2019. Equol production status was determined by measuring spot urine levels of equol, and risks of locomotive syndrome were evaluated by vulnerable fracture history and loco-check, a simple questionnaire comprising seven questions that can describe locomotive syndrome. Equol production (≥1 μmol/L in a spot urine sample) was found in 46 women (39.6%). Loss of equol production contributes to some lococheck items, which correlate with weakness of lower limb muscle strength (P < 0.05). In this study population, 57 women (49.1%) had previous vulnerable fractures. However, equol production status was not significantly related to the vulnerable fracture in this study population (P = 0.159). Equol production might contribute to the induction of locomotive syndrome, at least in part. However, equol deficiency as a mechanism of locomotive syndrome induction might not be the primary cause of a previous vulnerable fracture in very elderly women who live in nursing homes.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49396702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-03DOI: 10.37290/ijpp2641-7197.17:53-59
Lih-Ren Kong, Hsin-Ya Lin, Min-Shan Hsiao, Shu-Ching Wang
Probiotics have been shown to assist weight loss in overweight people. This study investigated the effects of a synbiotic supplement that comprised a prebiotic and a probiotic on anthropometric and biochemical measures in overweight and obese subjects. The synbiotic supplement used in this study contained Lactobacillus johnsonii No.1088, Bacillus subtilis (BS139), fermented sake lees, and green tea essence. Forty subjects with a body mass index ranging from 27 to 35 were recruited for this randomized, double-blind, placebo-controlled trial. At baseline and at the end of the 12-week trial, body composition and anthropometric parameter measurements were taken, blood biochemical analyses were performed, and fecal samples of the subjects were examined for gut microbiota diversity. Our results showed the synbiotic supplementation in this study did not affect normal liver and kidney function but significantly reduced body weight, body mass index, and waist and hip circumference. Total cholesterol and low-density lipoprotein cholesterol levels were also significantly reduced in subjects in the synbiotic supplementation group. Additionally, both fecal culture and urea breath testing showed inhibition of Helicobacter pylori infection in the subjects with synbiotic supplementation. The synbiotic supplementation in our study had promising effects in terms of weight loss, reduction of total cholesterol and low-density lipoprotein cholesterol levels, and inhibitory activity against H. pylori bacteria.
{"title":"Synbiotic Supplementation Facilitates Weight Loss, Improves Lipid Profile and Gut Health in Overweight and Obese Subjects","authors":"Lih-Ren Kong, Hsin-Ya Lin, Min-Shan Hsiao, Shu-Ching Wang","doi":"10.37290/ijpp2641-7197.17:53-59","DOIUrl":"https://doi.org/10.37290/ijpp2641-7197.17:53-59","url":null,"abstract":"Probiotics have been shown to assist weight loss in overweight people. This study investigated the effects of a synbiotic supplement that comprised a prebiotic and a probiotic on anthropometric and biochemical measures in overweight and obese subjects. The synbiotic supplement used in this study contained Lactobacillus johnsonii No.1088, Bacillus subtilis (BS139), fermented sake lees, and green tea essence. Forty subjects with a body mass index ranging from 27 to 35 were recruited for this randomized, double-blind, placebo-controlled trial. At baseline and at the end of the 12-week trial, body composition and anthropometric parameter measurements were taken, blood biochemical analyses were performed, and fecal samples of the subjects were examined for gut microbiota diversity. Our results showed the synbiotic supplementation in this study did not affect normal liver and kidney function but significantly reduced body weight, body mass index, and waist and hip circumference. Total cholesterol and low-density lipoprotein cholesterol levels were also significantly reduced in subjects in the synbiotic supplementation group. Additionally, both fecal culture and urea breath testing showed inhibition of Helicobacter pylori infection in the subjects with synbiotic supplementation. The synbiotic supplementation in our study had promising effects in terms of weight loss, reduction of total cholesterol and low-density lipoprotein cholesterol levels, and inhibitory activity against H. pylori bacteria.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44061980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-16DOI: 10.37290/ijpp2641-7197.17:47-52
Y. Kadota, Y. Koga, T. Tochio, R. Shibata
Several objective evaluation methods are used to evaluate treatment outcomes in atopic dermatitis clinical trials. We previously demonstrated the clinical efficacy of 1-kestose, the smallest fructooligosaccharide, in the treatment of atopic dermatitis in infants using an objective evaluation method. The utility of the Patient-Oriented Eczema Measure, in which patients themselves or their guardians evaluate the pathophysiology of atopic dermatitis, has recently been reported. In the present study, we used the Patient-Oriented Eczema Measure to confirm the efficiency of the clinical effect of 1-kestose on pediatric atopic dermatitis. An open pilot study was conducted on 22 children with atopic dermatitis. Subjects were orally administered 2 g of 1-kestose daily for 12 weeks and the symptoms of atopic dermatitis were evaluated using the Patient-Oriented Eczema Measure. The median total score of the Patient-Oriented Eczema Measure was significantly decreased by the 1-kestose treatment from 14.2 to 7.7 (P < 0.001). There was no correlation between decreases in the total score of the Patient-Oriented Eczema Measure and the age of subjects. Although the present study was a small pilot study, results suggest that 1-kestose may have attenuated atopic dermatitis to a degree that the patients themselves could recognize.
{"title":"Subjective Evaluation Using Patient-Oriented Eczema Measure of the Clinical Effects of 1-Kestose on Atopic Dermatitis in Children: A Pilot Study","authors":"Y. Kadota, Y. Koga, T. Tochio, R. Shibata","doi":"10.37290/ijpp2641-7197.17:47-52","DOIUrl":"https://doi.org/10.37290/ijpp2641-7197.17:47-52","url":null,"abstract":"Several objective evaluation methods are used to evaluate treatment outcomes in atopic dermatitis clinical trials. We previously demonstrated the clinical efficacy of 1-kestose, the smallest fructooligosaccharide, in the treatment of atopic dermatitis in infants using an objective evaluation method. The utility of the Patient-Oriented Eczema Measure, in which patients themselves or their guardians evaluate the pathophysiology of atopic dermatitis, has recently been reported. In the present study, we used the Patient-Oriented Eczema Measure to confirm the efficiency of the clinical effect of 1-kestose on pediatric atopic dermatitis. An open pilot study was conducted on 22 children with atopic dermatitis. Subjects were orally administered 2 g of 1-kestose daily for 12 weeks and the symptoms of atopic dermatitis were evaluated using the Patient-Oriented Eczema Measure. The median total score of the Patient-Oriented Eczema Measure was significantly decreased by the 1-kestose treatment from 14.2 to 7.7 (P < 0.001). There was no correlation between decreases in the total score of the Patient-Oriented Eczema Measure and the age of subjects. Although the present study was a small pilot study, results suggest that 1-kestose may have attenuated atopic dermatitis to a degree that the patients themselves could recognize.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43188493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-04DOI: 10.37290/ijpp2641-7197.18:1-6
Ninung Rd Kusumawati, Mira M Ulfah, D. G. Panunggal, S. Sudarmo, Maria Agustini Utari, M. Sidhartani
Intestinal barrier function, critical for maintaining optimal gut health, is achieved primarily through mucins and tight junction proteins (i.e., zonula occludens-1 and occludin). An aberrant expression of these proteins results in increased paracellular permeability, leading to nonalcoholic steatohepatitis. Furthermore, enhanced expression of the inflammasome’s nucleotide-binding domain, leucine-rich repeat-containing protein 3 (cryopyrin), and Toll-like receptor 4 are also associated with nonalcoholic steatohepatitis. To understand the role of probiotic supplementation (Lactobacillus acidophilus, Bifidobacterium longum, and Streptococcus thermophilus) in rats on a high-fat, high-fructose diet with nonalcoholic steatohepatitis, the expression of occludin, cryopyrin, and Toll-like receptor 4 was evaluated. A comparison of the results between the control, nonalcoholic steatohepatitis group, and probiotic-treated nonalcoholic steatohepatitis groups showed (a) a lack of any significant difference in occluding expression (P = 0.724) and (b) a significant reduction in serum Toll-like receptor 4 (P = 0.012) and cryopyrin (P = 0.025) by probiotics. Furthermore, only one rat developed nonalcoholic steatohepatitis in the probiotic group, compared to six rats in the non-probiotic group. In conclusion, there were hepatoprotective effects of probiotic administration on high-fat, high-fructose diet-induced nonalcoholic steatohepatitis in Sprague-Dawley rats.
{"title":"Hepatoprotective Effects of Probiotic Administration on High Fat-High Fructose Diet Induced Nonalcoholic Steatohepatitis in Sprague-Dawley Rats","authors":"Ninung Rd Kusumawati, Mira M Ulfah, D. G. Panunggal, S. Sudarmo, Maria Agustini Utari, M. Sidhartani","doi":"10.37290/ijpp2641-7197.18:1-6","DOIUrl":"https://doi.org/10.37290/ijpp2641-7197.18:1-6","url":null,"abstract":"Intestinal barrier function, critical for maintaining optimal gut health, is achieved primarily through mucins and tight junction proteins (i.e., zonula occludens-1 and occludin). An aberrant expression of these proteins results in increased paracellular permeability, leading to nonalcoholic steatohepatitis. Furthermore, enhanced expression of the inflammasome’s nucleotide-binding domain, leucine-rich repeat-containing protein 3 (cryopyrin), and Toll-like receptor 4 are also associated with nonalcoholic steatohepatitis. To understand the role of probiotic supplementation (Lactobacillus acidophilus, Bifidobacterium longum, and Streptococcus thermophilus) in rats on a high-fat, high-fructose diet with nonalcoholic steatohepatitis, the expression of occludin, cryopyrin, and Toll-like receptor 4 was evaluated. A comparison of the results between the control, nonalcoholic steatohepatitis group, and probiotic-treated nonalcoholic steatohepatitis groups showed (a) a lack of any significant difference in occluding expression (P = 0.724) and (b) a significant reduction in serum Toll-like receptor 4 (P = 0.012) and cryopyrin (P = 0.025) by probiotics. Furthermore, only one rat developed nonalcoholic steatohepatitis in the probiotic group, compared to six rats in the non-probiotic group. In conclusion, there were hepatoprotective effects of probiotic administration on high-fat, high-fructose diet-induced nonalcoholic steatohepatitis in Sprague-Dawley rats.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44626236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-20DOI: 10.37290/ijpp2641-7197.17:42-46
R. Ranuh, Sitti Radhiah, K. Sumitro, A. Darma, A. F. Athiyyah, Dwiyanti Puspitasari, D. Husada, A. Endaryanto, I. Surono, S. Sudarmo
Human immunodeficiency virus infection is associated with impairment of T helper 1, T helper 2, regulatory T, and T helper Type 17 homeostasis. While probiotics are widely known to improve these changes, understanding of their role on children’s immune system remains limited. In a randomized, double-blind, and placebo-controlled study conducted in Dr. Soetomo General Hospital, Surabaya from December 2012 to March 2013, we have investigated the effect of Lactobacillus plantarum IS-10506 on the regulation of T helper and regulatory T cell in children infected with human immunodeficiency virus receiving antiretroviral therapy for at least 6 months. Twenty-one human immunodeficiency virus infected children were divided into placebo and probiotic groups and L. plantarum IS-10506 was administered at a dose of 2.86 × 1010 colony forming units/day for 6 weeks. Levels of interferon-γ, interleukin-4, transforming growth factor-β, and interleukin-17 were analyzed before and after treatment as an indicator of T-cell regulation of T helper and regulatory T cells. The results show a significant increase in transforming growth factor-β level ( p = 0.003) after administration of L. plantarum IS-10506 compared to placebo with the first-line antiretroviral therapy group. There was no reported adverse effect in this study. In conclusion, L. plantarum IS-10506 increases the regulation of regulatory T cell in human immunodeficiency virus infection in children receiving first-line antiretroviral therapy treatment.
人类免疫缺陷病毒感染与辅助性T 1、辅助性T 2、调节性T和辅助性T 17型体内平衡受损有关。虽然益生菌被广泛认为可以改善这些变化，但对它们对儿童免疫系统的作用的理解仍然有限。2012年12月至2013年3月，我们在泗水Soetomo总医院进行了一项随机、双盲、安慰剂对照的研究，研究了植物乳杆菌IS-10506对接受抗逆转录病毒治疗至少6个月的人类免疫缺陷病毒感染儿童辅助性T细胞和调性T细胞的调节作用。将21例人类免疫缺陷病毒感染儿童分为安慰剂组和益生菌组，以2.86 × 1010菌落形成单位/天的剂量给予植物乳杆菌IS-10506，持续6周。分析治疗前后的干扰素-γ、白细胞介素-4、转化生长因子-β和白细胞介素-17水平，作为T细胞对辅助性T细胞和调节性T细胞调节的指标。结果显示，与安慰剂和一线抗逆转录病毒治疗组相比，给予植物乳杆菌IS-10506后转化生长因子-β水平显著升高(p = 0.003)。本研究未发现不良反应。总之，L. plantarum IS-10506在接受一线抗逆转录病毒治疗的儿童中增加了调节性T细胞在人类免疫缺陷病毒感染中的调节作用。
{"title":"Regulation of T Helper and Regulatory T Cells by Lactobacillus Plantarum IS-10506 Supplementation to Human Immunodeficiency Virus-Infected Children Under Antiretroviral Therapy","authors":"R. Ranuh, Sitti Radhiah, K. Sumitro, A. Darma, A. F. Athiyyah, Dwiyanti Puspitasari, D. Husada, A. Endaryanto, I. Surono, S. Sudarmo","doi":"10.37290/ijpp2641-7197.17:42-46","DOIUrl":"https://doi.org/10.37290/ijpp2641-7197.17:42-46","url":null,"abstract":"Human immunodeficiency virus infection is associated with impairment of T helper 1, T helper 2, regulatory T, and T helper Type 17 homeostasis. While probiotics are widely known to improve these changes, understanding of their role on children’s immune system remains limited. In a randomized, double-blind, and placebo-controlled study conducted in Dr. Soetomo General Hospital, Surabaya from December 2012 to March 2013, we have investigated the effect of Lactobacillus plantarum IS-10506 on the regulation of T helper and regulatory T cell in children infected with human immunodeficiency virus receiving antiretroviral therapy for at least 6 months. Twenty-one human immunodeficiency virus infected children were divided into placebo and probiotic groups and L. plantarum IS-10506 was administered at a dose of 2.86 × 1010 colony forming units/day for 6 weeks. Levels of interferon-γ, interleukin-4, transforming growth factor-β, and interleukin-17 were analyzed before and after treatment as an indicator of T-cell regulation of T helper and regulatory T cells. The results show a significant increase in transforming growth factor-β level ( p = 0.003) after administration of L. plantarum IS-10506 compared to placebo with the first-line antiretroviral therapy group. There was no reported adverse effect in this study. In conclusion, L. plantarum IS-10506 increases the regulation of regulatory T cell in human immunodeficiency virus infection in children receiving first-line antiretroviral therapy treatment.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43560383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-30DOI: 10.37290/ijpp2641-7197.17:33-41
P. Rysavka, M. Kohutková-Lánová, R. Netušil, E. Pospíšilová, M. Hanácˇková, J. Cˇmielová, K. Št’astný, I. Márová, M. Haranta, A. Bomba
The current market of probiotic supplements is significantly growing although the quality and effectiveness of the commonly sold products are variable. Parameters such as the composition of each individual microbiota, strain specificity, production procedures, or storage can influence the potential positive outcome of probiotic supplements on consumers. The aim of this study was to determine changes of selected markers within the microbiota after 3 months treatment by the personalized probiotic supplement. Stool samples of 48 volunteers were analyzed by 16s ribsosomal RNA sequencing. The composition (selection of species, number of species used, and number of colony-forming units) of the probiotic mixture was designed based on the gut microbiota analysis and it was prepared for each patient separately. After 3 months of probiotic supplementation, a control sample was analyzed. Data confirmed a statistically significant increase in abundance of genera Lactobacillus and Bifidobacterium and phylum Actinobacteria. The overall number of species was also increased thus increasing the overall diversity of the microbiota, which is considered a marker of healthy gut microbiota.
{"title":"Targeted Modulation of Gut Microbiota by Personalized Probiotics","authors":"P. Rysavka, M. Kohutková-Lánová, R. Netušil, E. Pospíšilová, M. Hanácˇková, J. Cˇmielová, K. Št’astný, I. Márová, M. Haranta, A. Bomba","doi":"10.37290/ijpp2641-7197.17:33-41","DOIUrl":"https://doi.org/10.37290/ijpp2641-7197.17:33-41","url":null,"abstract":"The current market of probiotic supplements is significantly growing although the quality and effectiveness of the commonly sold products are variable. Parameters such as the composition of each individual microbiota, strain specificity, production procedures, or storage can influence the potential positive outcome of probiotic supplements on consumers. The aim of this study was to determine changes of selected markers within the microbiota after 3 months treatment by the personalized probiotic supplement. Stool samples of 48 volunteers were analyzed by 16s ribsosomal RNA sequencing. The composition (selection of species, number of species used, and number of colony-forming units) of the probiotic mixture was designed based on the gut microbiota analysis and it was prepared for each patient separately. After 3 months of probiotic supplementation, a control sample was analyzed. Data confirmed a statistically significant increase in abundance of genera Lactobacillus and Bifidobacterium and phylum Actinobacteria. The overall number of species was also increased thus increasing the overall diversity of the microbiota, which is considered a marker of healthy gut microbiota.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47995677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-11DOI: 10.37290/ijpp2641-7197.17:27-32
S. Sudarmo, R. Ranuh, A. F. Athiyyah, A. Darma, Virany Diana, B. Hidajat, Siti Nurul Hidayati, A. Endaryanto
Prevention of diarrhea needs an appropriate immune system supported by normal microbiota composition. This study aimed to determine whether probiotic or prebiotic enriched Growing-Up Milk could significantly reduce incidence of acute diarrhea. The randomized, double-blind, placebo-controlled clinical study was conducted in Surabaya, Gresik, and Sidoarjo cities, East Java–Indonesia, between July 2007 and January 2008. This study involved healthy children aged 1–5 years at day-care centers and were randomized to receive three different Growing-Up Milk containing probiotic, prebiotic, or placebo groups (containing neither probiotic nor prebiotic). The day-care staff and parents reported the amount of milk consumed, symptoms, and duration of acute diarrhea during the observation time. A total of 162 participants were divided into probiotic (55), prebiotic (54), and placebo groups (53). The incidence of diarrhea in all the participants was 1.2%, which was the least incidence from the prebiotic group and the highest in the placebo group and significantly different (P = 0.001). The mean duration of diarrhea in all the intervention groups was lower than the placebo group, although neither was statistically nor clinically significant (P = 0.254). Administration of Growing-Up Milk enriched with probiotics or prebiotics appears to be a great opportunity in reducing the incidence of acute diarrhea in children aged 1–5 years.
{"title":"The Effects of Probiotic and Prebiotic Administration in Children with Acute Diarrhea at Day-Care Centers","authors":"S. Sudarmo, R. Ranuh, A. F. Athiyyah, A. Darma, Virany Diana, B. Hidajat, Siti Nurul Hidayati, A. Endaryanto","doi":"10.37290/ijpp2641-7197.17:27-32","DOIUrl":"https://doi.org/10.37290/ijpp2641-7197.17:27-32","url":null,"abstract":"Prevention of diarrhea needs an appropriate immune system supported by normal microbiota composition. This study aimed to determine whether probiotic or prebiotic enriched Growing-Up Milk could significantly reduce incidence of acute diarrhea. The randomized, double-blind, placebo-controlled clinical study was conducted in Surabaya, Gresik, and Sidoarjo cities, East Java–Indonesia, between July 2007 and January 2008. This study involved healthy children aged 1–5 years at day-care centers and were randomized to receive three different Growing-Up Milk containing probiotic, prebiotic, or placebo groups (containing neither probiotic nor prebiotic). The day-care staff and parents reported the amount of milk consumed, symptoms, and duration of acute diarrhea during the observation time. A total of 162 participants were divided into probiotic (55), prebiotic (54), and placebo groups (53). The incidence of diarrhea in all the participants was 1.2%, which was the least incidence from the prebiotic group and the highest in the placebo group and significantly different (P = 0.001). The mean duration of diarrhea in all the intervention groups was lower than the placebo group, although neither was statistically nor clinically significant (P = 0.254). Administration of Growing-Up Milk enriched with probiotics or prebiotics appears to be a great opportunity in reducing the incidence of acute diarrhea in children aged 1–5 years.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43606051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-11DOI: 10.37290/ijpp2641-7197.17:21-26
R. Ranuh, A. F. Athiyyah, A. Darma, W. Riawan, P. Gunawan, I. Surono, S. Sudarmo
Gut microbiota is a complex community that helps maintain the dynamic metabolic ecological balance of the brain through the gut–brain axis and keeps the blood–brain barrier structure intact. However, the knowledge of how the gut microbiota responds to exogenous influences on the blood–brain barrier structure remains limited. This study hypothesizes that probiotic Lactobacillus plantarum IS 10506 supplementations could ameliorate the disruption of the blood–brain barrier structure. To this end, we examined effect of the probiotic L. plantarum IS 10506 on the expression of glial fibrillary acidic protein and platelet endothelial cell adhesion molecule-1 in the control and E. coli serotype O55:B5 lipopolysaccharide treated blood–brain barrier disruption model of Wistar rats. The rats receiving L. plantarum IS 10506 alone or along with E. coli serotype O55:B5 lipopolysaccharide exhibited upregulation of the expression of glial fibrillary acidic protein and platelet endothelial cell adhesion molecule-1. In conclusion, the probiotic L. plantarum IS-10506 stimulates the restoration of blood–brain barrier disruption.
{"title":"Probiotic Lactobacillus plantarum IS-10506, Expression of Glial Fibrillary Acidic Protein and Platelet Endothelial Cell Adhesion Molecule-1 by Astrocytes and Endothelial Integrity: The Importance of Intestinal Microbiota as Blood Brain–Barrier Stabilizer","authors":"R. Ranuh, A. F. Athiyyah, A. Darma, W. Riawan, P. Gunawan, I. Surono, S. Sudarmo","doi":"10.37290/ijpp2641-7197.17:21-26","DOIUrl":"https://doi.org/10.37290/ijpp2641-7197.17:21-26","url":null,"abstract":"Gut microbiota is a complex community that helps maintain the dynamic metabolic ecological balance of the brain through the gut–brain axis and keeps the blood–brain barrier structure intact. However, the knowledge of how the gut microbiota responds to exogenous influences on the blood–brain barrier structure remains limited. This study hypothesizes that probiotic Lactobacillus plantarum IS 10506 supplementations could ameliorate the disruption of the blood–brain barrier structure. To this end, we examined effect of the probiotic L. plantarum IS 10506 on the expression of glial fibrillary acidic protein and platelet endothelial cell adhesion molecule-1 in the control and E. coli serotype O55:B5 lipopolysaccharide treated blood–brain barrier disruption model of Wistar rats. The rats receiving L. plantarum IS 10506 alone or along with E. coli serotype O55:B5 lipopolysaccharide exhibited upregulation of the expression of glial fibrillary acidic protein and platelet endothelial cell adhesion molecule-1. In conclusion, the probiotic L. plantarum IS-10506 stimulates the restoration of blood–brain barrier disruption.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45304409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-27DOI: 10.37290/ijpp2641-7197.17:1-13
N. P. Hardjo Lugito, R. Djuwita, A. Adisasmita, M. Simadibrata
We have conducted a systematic investigation on the role of Lactobacillus on blood pressure by a meta-analysis of randomized controlled trials. The PubMed, Scopus, and Google Scholar were used to identify eligible trials from January 2000 until February 2021. Random-effects model was used to assess the treatment effect, i.e., mean difference of systolic and diastolic blood pressure. We further conducted sensitivity and stratified analyses. As many as 23 studies with 2,399 subjects were included in the meta-analysis. The pooled standardized mean difference of systolic blood pressure was −0.71 mmHg, 95% confidence interval −1.02 to −0.41, P < 0.00001, test for heterogeneity P < 0.00001; I2 = 92% and diastolic blood pressure was −0.45 mmHg, 95% confidence interval −0.72 to −0.18, P < 0.001, test for heterogeneity P < 0.001; I2 = 90. The findings of this meta-analysis showed that Lactobacillus exerted significant systolic and diastolic blood pressure lowering effect compared to placebo. The subgroup analysis showed that single strain of Lactobacillus exerted more blood pressure lowering effect compared to the multi-strain probiotics. Despite these significant results, the studies included had significant heterogeneity even after sensitivity analysis.
{"title":"Blood Pressure Lowering Effect of Lactobacillus-Containing Probiotic","authors":"N. P. Hardjo Lugito, R. Djuwita, A. Adisasmita, M. Simadibrata","doi":"10.37290/ijpp2641-7197.17:1-13","DOIUrl":"https://doi.org/10.37290/ijpp2641-7197.17:1-13","url":null,"abstract":"We have conducted a systematic investigation on the role of Lactobacillus on blood pressure by a meta-analysis of randomized controlled trials. The PubMed, Scopus, and Google Scholar were used to identify eligible trials from January 2000 until February 2021. Random-effects model was used to assess the treatment effect, i.e., mean difference of systolic and diastolic blood pressure. We further conducted sensitivity and stratified analyses. As many as 23 studies with 2,399 subjects were included in the meta-analysis. The pooled standardized mean difference of systolic blood pressure was −0.71 mmHg, 95% confidence interval −1.02 to −0.41, P < 0.00001, test for heterogeneity P < 0.00001; I2 = 92% and diastolic blood pressure was −0.45 mmHg, 95% confidence interval −0.72 to −0.18, P < 0.001, test for heterogeneity P < 0.001; I2 = 90. The findings of this meta-analysis showed that Lactobacillus exerted significant systolic and diastolic blood pressure lowering effect compared to placebo. The subgroup analysis showed that single strain of Lactobacillus exerted more blood pressure lowering effect compared to the multi-strain probiotics. Despite these significant results, the studies included had significant heterogeneity even after sensitivity analysis.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41354470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-11DOI: 10.37290/ijpp2641-7197.17:14-20
J. Paek, B. Kang, H. Yang, Y. Lee
Lactobacillus fermentum PL9988 was isolated from an elderly person over 80 years of age living in a Korean longevity village. Results from a previous study showed various characteristics of L. fermentum PL9988 as a probiotic, including resistance to acid and bile acid, immune-enhancing activity, adhesiveness to the intestinal cell line Caco-2, inhibition of various intestinal pathogens, antioxidation activity, and susceptibility to antimicrobials. In this study, the binding activity of L. fermentum PL9988 to the intestine was confirmed in another human intestinal cell line, HT-29, and mouse intestinal cells. The anti-inflammatory activity of L. fermentum PL9988 was examined via both in vitro and in vivo experiments. Lactobacillus fermentum PL9988 increased the amount of IL-10 and decreased the amount of TNF-α in HT-29 cells treated with LPS. Similar results were observed in an in vivo experiment with BALB/c mice fed L. fermentum PL9988. Thus, results from the previous study and this study demonstrate the beneficial characteristics of L. fermentum PL9988 as a good probiotic with anti-inflammatory, antioxidative, and immune-enhancing activities in addition to improving intestinal health.
{"title":"Binding to Intestinal Epithelial Cells and Anti-Inflammatory Activity of Lactobacillus fermentum PL9988","authors":"J. Paek, B. Kang, H. Yang, Y. Lee","doi":"10.37290/ijpp2641-7197.17:14-20","DOIUrl":"https://doi.org/10.37290/ijpp2641-7197.17:14-20","url":null,"abstract":"Lactobacillus fermentum PL9988 was isolated from an elderly person over 80 years of age living in a Korean longevity village. Results from a previous study showed various characteristics of L. fermentum PL9988 as a probiotic, including resistance to acid and bile acid, immune-enhancing activity, adhesiveness to the intestinal cell line Caco-2, inhibition of various intestinal pathogens, antioxidation activity, and susceptibility to antimicrobials. In this study, the binding activity of L. fermentum PL9988 to the intestine was confirmed in another human intestinal cell line, HT-29, and mouse intestinal cells. The anti-inflammatory activity of L. fermentum PL9988 was examined via both in vitro and in vivo experiments. Lactobacillus fermentum PL9988 increased the amount of IL-10 and decreased the amount of TNF-α in HT-29 cells treated with LPS. Similar results were observed in an in vivo experiment with BALB/c mice fed L. fermentum PL9988. Thus, results from the previous study and this study demonstrate the beneficial characteristics of L. fermentum PL9988 as a good probiotic with anti-inflammatory, antioxidative, and immune-enhancing activities in addition to improving intestinal health.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44965439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：